Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

Posted: October 13, 2022 at 2:26 am

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022. The posters will share findings from several studies surrounding adintrevimab, including data from the Phase 1 and Phase 2/3 clinical trials.

Go here to see the original:
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

Related Posts